1-4 of 4
Mark E. Burkard
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation

Cheri A. Pasch, Peter F. Favreau, Alexander E. Yueh, Christopher P. Babiarz, Amani A. Gillette, Joe T. Sharick, Mohammad Rezaul Karim, Kwangok P. Nickel, Alyssa K. DeZeeuw, Carley M. Sprackling, Philip B. Emmerich, Rebecca A. DeStefanis, Rosabella T. Pitera, Susan N. Payne, Demetra P. Korkos, Linda Clipson, Christine M. Walsh, Devon Miller, Evie H. Carchman, Mark E. Burkard, Kayla K. Lemmon, Kristina A. Matkowskyj, Michael A. Newton, Irene M. Ong, Michael F. Bassetti, Randall J. Kimple, Melissa C. Skala, Dustin A. Deming
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5376–5387.
https://doi.org/10.1158/1078-0432.CCR-18-3590
Published: 03 September 2019
View article titled, Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation
Open the PDF for Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation in another window
Includes: Supplementary data
Journal Articles

A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III PIK3CA-Mutant ER-Positive and HER2-Negative Breast Cancer

Cynthia X. Ma, Vera Suman, Matthew P. Goetz, Donald Northfelt, Mark E. Burkard, Foluso Ademuyiwa, Michael Naughton, Julie Margenthaler, Rebecca Aft, Richard Gray, Amye Tevaarwerk, Lee Wilke, Tufia Haddad, Timothy Moynihan, Charles Loprinzi, Tina Hieken, Erica K. Barnell, Zachary L. Skidmore, Yan-Yang Feng, Kilannin Krysiak, Jeremy Hoog, Zhanfang Guo, Leslie Nehring, Kari B. Wisinski, Elaine Mardis, Ian S. Hagemann, Kiran Vij, Souzan Sanati, Hussam Al-Kateb, Obi L. Griffith, Malachi Griffith, Laurence Doyle, Charles Erlichman, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (22): 6823–6832.
https://doi.org/10.1158/1078-0432.CCR-17-1260
Published: 14 November 2017
View article titled, A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <em>PIK3CA</em>-Mutant ER-Positive and HER2-Negative Breast Cancer
Open the PDF for A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <em>PIK3CA</em>-Mutant ER-Positive and HER2-Negative Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A01: Centrosome amplification induces autophagy and sensitizes to chloroquine

Ryan A. Denu, Mark E. Burkard
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (1_Supplement): A01.
https://doi.org/10.1158/1557-3265.PMCCAVULN16-A01
Published: 02 January 2017
View article titled, Abstract A01: Centrosome amplification induces autophagy and sensitizes to chloroquine
Journal Articles

Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer

Kari B. Wisinski, Amye J. Tevaarwerk, Mark E. Burkard, Murtuza Rampurwala, Jens Eickhoff, Maria C. Bell, Jill M. Kolesar, Christopher Flynn, Glenn Liu
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (11): 2659–2667.
https://doi.org/10.1158/1078-0432.CCR-15-2365
Published: 31 May 2016
View article titled, Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer
Open the PDF for Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2<sup>+</sup> Breast Cancer in another window